HeartWare International Inc

HeartWare International — Technical Presentation (April 2010)

21 slides from HeartWare International's technical presentation, Apr 23, 2010

  1. Slide 1: HeartWare Ventricular Assist System Technology & Surgical Overview

    HeartWare(r) Ventricular Assist System Technology & Surgical Overview Martin Strueber, MD Hannover Medical School

  2. Slide 2: Evaluation of the Minimally Invasive HeartWare Ventricular Assist System as a Long Term Support Device

    EVALUATION OF THE MINIMALLY INVASIVE HEARTWARE VENTRICULAR ASSIST SYSTEM AS A LONG TERM SUPPORT DEVICE Martin Strueber, Hannover, Germany; Paul Jansz, Sydney, Australia; George Wieselthaler, Vienna, Austria; Gerry O^Driscoll, Perth, Australia; Michiel Morshuis, Bad Oeynhausen, Germany; Asghar Khagha

  3. Slide 3: Global Clinical Experience Overview

    Global Clinical Experience Overview The HeartWare Ventricular Assist System is the newest circulatory support device to be commercially launched in Europe More than 300 implants to date worldwide Initial clinical trial enrolled 50 patients in Europe and Australia - enrollment completed Dec 2008 CE M

  4. Slide 4: Implants Across Five Countries

    100 Implants Across Five Countries Australia Paul Jansz, St. Vincent's, Sydney Gerry O^Driscoll, Royal Perth Hospital Austria Georg Wieselthaler, University of Vienna France Daniel Duveau, Hopital Guillaume et Rene Laennec, Nantes Germany Roland Hetzer, Deutsches Herzzentrum Berlin Andreas Hoffmeier

  5. Slide 5: The HeartWare Ventricular Assist System

    The HeartWare Ventricular Assist System HVAD miniaturized implantable blood pump 10 liters of flow Implanted in the pericardial space Via median sternotomy or left thoracotomy No surgical pump pocket Centrifugal flow with Hydromagnetic suspension Wear-less, wide channel impeller design Design optimi

  6. Slide 6: Demographics

    Age (years) BSA (m2) Weight (Kg) Mean 50.5 1.94 78.2 SD 13.6 0.23 17.0 Median 54 1.9 75 Min 16 1.39 43 Max 74 2.56 138 Demographics

  7. Slide 7: Gender

    Gender = Male Female

  8. Slide 8: Operative

    Operative = Sternotomy ™ Thoracotomy Cardiopulmonary Bypass 2% = Off Pump m™On Pump

  9. Slide 9: Operative Approach at Implant

    Operative Approach at Implant

  10. Slide 10: Etiology of Heart Failure

    Etiology of Heart Failure Ischemic = Non Ischemic

  11. Slide 11: INTERMACS Score Pre-Implant

    INTERMACS Score Pre-Implant N= 43 for Commercial cohort

  12. Slide 12: Duration of Support (days)

    Clinical Trial (n =50) Commercial (n = 50) Mean 444.4 203.8 SD 287 90 Median 449 198 Min 12 3 Max 1108 392 Duration of Support (days)

  13. Slide 13: Adverse Events and Rates (n = 100)

    % Patients Affected Event Rate Respiratory Failure 15% 0.17 Renal Failure 9% 0.10 Infection - Sepsis 9% 0.10 Infection - Driveline 15% 0.17 Stroke Ischemic 4% 0.05 Hemorrhagic 7% 0.08 * Pagani et al. Extended Mechanical Circulatory Support With a Continuous-Flow Rotary Left Ventricular Assist Device

  14. Slide 14: Infections

    Infections Clinical Trial (n = 50) Commercial (n = 50) Sepsis 4 5 Driveline 9 6

  15. Slide 15: Neurologic Events Post Implant (All)

    Neurologic Events Post Implant (All) Clinical Trial (n = 50) Commercial (n = 50) CVA Ischemic 2 2 Hemorrhagic 5 2 TIA 2 2

  16. Slide 16: RVAD Post Implant

    RVAD Post Implant Clinical Trial (n = 50) Commercial (n = 50) Need for RVAD 3 2

  17. Slide 17: Pump Exchanges

    Pump Exchanges Number of patients LJ ° Clinical Trial Commercial

  18. Slide 18: Current Status

    Current Status Clinical Trial (n = 50) Commercial (n = 50) Alive at 180 days 45 (90%) 45 (90%) Transplanted at 180 Days 7 4 Mean Time to Transplant 331 Days 133 Days Median Duration (All) 449 Days 199 Days Average Duration (All) 444 Days 204 Days

  19. Slide 19: Kaplan-Meier Survival Curve

    Kaplan-Meier Survival Curve 90% 180 days 85% 77% Clinical Trial Patients (n =50) Commercial Patients (n = 50) 180 days 90% 87%

  20. Slide 20: Kaplan-Meier Survival Curve: Clinical & Commercial (n = 100)

    Kaplan-Meier Survival Curve 90% 86% 78% 180 days Clinical & Commercial (n = 100)

  21. Slide 21: Conclusions

    Long term circulatory support with the miniature HeartWare Ventricular Assist System is feasible The device performs well for greater than one year with low adverse event rates The data also demonstrate versatility of the HeartWare System to support a wide range of patients Minimally invasive implan

HeartWare International — Technical Presentation (April 2010) on 6ix